PRIMATENE MIST
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PRIMATENE MIST (PRIMATENE MIST).
Epinephrine is a sympathomimetic amine that acts as a non-selective agonist at alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors. Activation of beta-2 receptors in bronchial smooth muscle causes relaxation and bronchodilation, relieving bronchospasm. Alpha-adrenergic activation can cause vasoconstriction and reduce mucosal edema.
| Metabolism | Epinephrine is metabolized primarily by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) in the liver and other tissues, forming inactive metabolites like metanephrine and vanillylmandelic acid (VMA). |
| Excretion | Renal excretion: approximately 60-70% as unchanged drug and metabolites. Biliary/fecal: minor, less than 10%. |
| Half-life | Terminal elimination half-life: 3-4 hours. Clinical context: Requires repeated dosing for sustained bronchodilation; shorter half-life necessitates q4-6h dosing. |
| Protein binding | 15-20% bound to albumin. |
| Volume of Distribution | Vd: 2-3 L/kg. Indicates extensive tissue distribution, not confined to plasma. |
| Bioavailability | Inhalation: 10-20% (due to pulmonary deposition and first-pass metabolism). |
| Onset of Action | Inhalation: 5-15 minutes. |
| Duration of Action | 2-4 hours. Clinical notes: Tolerance may develop with frequent use, reducing duration. |
1-2 inhalations (0.5-1 mg epinephrine base) as a single dose; may repeat every 3-4 hours as needed, not to exceed 12 inhalations in 24 hours.
| Dosage form | AEROSOL, METERED |
| Renal impairment | No specific GFR-based dose modifications established; use with caution in severe renal impairment due to potential accumulation of metabolites. |
| Liver impairment | No specific Child-Pugh based dose modifications; caution in severe hepatic impairment due to reduced clearance. |
| Pediatric use | Children <4 years: not recommended. Children 4-12 years: 1 inhalation (0.5 mg epinephrine base) every 3-4 hours as needed, not to exceed 8 inhalations in 24 hours. Children >12 years: same as adult dosing. |
| Geriatric use | Initiate with lowest effective dose (1 inhalation) due to increased sensitivity and higher risk of adverse cardiac effects; monitor closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PRIMATENE MIST (PRIMATENE MIST).
| Breastfeeding | Epinephrine is excreted into breast milk in minimal amounts. M/P ratio not established. Oral bioavailability is low, so systemic effects in infant are unlikely. However, use with caution in breastfeeding women, especially with high doses or frequent use. Avoid nursing immediately after inhalation. |
| Teratogenic Risk | Primatene Mist contains epinephrine, a sympathomimetic amine. In pregnant women, epinephrine may cause fetal hypoxia due to uterine vasoconstriction. First trimester: limited data, but animal studies show teratogenic effects at high doses; avoid if possible. Second and third trimesters: use only if clearly needed; may reduce uterine blood flow and induce premature labor. Category C: risk cannot be ruled out. |
■ FDA Black Box Warning
None for PRIMATENE MIST specifically. However, epinephrine-containing products carry a warning for risk of serious adverse events due to inappropriate use.
| Serious Effects |
["Hypersensitivity to epinephrine or any component","Concurrent use with non-selective beta-blockers (e.g., propranolol) due to risk of severe hypertension and bronchospasm","Cardiac arrhythmias (e.g., ventricular fibrillation) or coronary insufficiency","Severe hypertension, hyperthyroidism, or narrow-angle glaucoma"]
| Precautions | ["May cause paradoxical bronchospasm: discontinue immediately if wheezing worsens","Overuse may lead to tolerance and increased risk of severe asthma attacks","Avoid in patients with significant cardiovascular disease, hypertension, hyperthyroidism, or diabetes unless directed by a physician","May cause palpitations, tachycardia, arrhythmias, and increased blood pressure"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and signs of cardiac arrhythmias. Assess fetal heart rate patterns for signs of distress. Monitor uterine activity for evidence of premature labor or hyperstimulation. Evaluate maternal respiratory status and bronchodilator response. |
| Fertility Effects | No specific studies on fertility effects in humans. In animal studies, epinephrine at high doses caused impaired fertility and increased preimplantation loss. Relevance to humans is unknown. May affect uterine contractility and implantation if used around conception. |